FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
30.0 pts (24h)Health & MedicineOne-Off3mois
KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Oui 97%+30.0pt
Qualité du marché
45 / 100
Faible qualitéVolume 24h
539,4 €
Liquidité
594,2 €
Faible liquiditéAchat / Vente
72.0% / 80.0%
Écart
8.0 pt
Spread largeDonnées du marché
Mis à jour il y a 4 minutes
17 juin 26, 21:30 UTC1 janv. 27, 04:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiFDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRègles
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Règlement via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
- Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
- In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Marchés ouverts
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume total
- 15,6 M €
- Volume 24h
- 18,3 k €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume total
- 1,6 M €
- Volume 24h
- 5,2 k €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 résultats de plus
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume total
- 916 k €
- Volume 24h
- 1,5 k €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 résultats de plus
- Volume total
- 863,6 k €
- Volume 24h
- 1 k €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Questions fréquentes
- Quelles sont les probabilités actuelles pour FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) ?
- Kalshi cote Yes à 97% au 8 septembre 2026.
- Quand FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) sera-t-il résolu ?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) doit être résolu le 1 janvier 2027.
- Comment FDA decision: Saroglitazar by Zydus Therapeutics (in 2026) est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.